13 September 2016
Vol 9, Issue 445

About The Cover

Cover image expansion

Online Cover This week features a pair of research articles that identify the DNA replication stress response and in particular the kinases CHK1 and ATR as therapeutic targets for treating acute myeloid leukemia (AML). David et al. identified CHK1 as an independent prognostic indicator, marker for patient stratification, and target for therapeutic intervention. Morgado-Palacin et al. used a mouse model of a particularly aggressive form of AML to show that inhibition of either ATR or the kinase ATM exhibited antitumoral activity, reducing the growth of established cancer and prolonging the animals' health and survival, even when used as monotherapies. Thus, dependence on the DNA replication stress response enables therapeutic targeting in AML. [Image: Lightspring/shutterstock]